Skip navigation


CALBIO2013 is a statewide conference that has a global focus on bringing together the life sciences sector in California and targeting delegates from around the world - nearly 1,100 company executives, innovators, government representatives, medical research and disease foundation representatives, university transfer officers, philanthropists and investors will attend.

. Biotechnology and pharmaceutical companies from California and globally, interested in exchange of best business and operational practices as well as non-profit/for-profit collaborations necessary for the successful commercialization of new therapies

. Investors from across the United States and abroad seeking to invest their funds in a targeted, efficient, and effective manner

. Medical research foundations and institutes that are outcomes-driven and strategic in their allocation of resources

. Thought leaders and innovators with diverse experiences and expertise all committed to expediting the research and development process

. University transfer offices focused on facilitating the transfer of university-developed research results to industry for commercial development purposes

An improved feature this year - Business Partnering:

There is no substitute for a face-to-face meeting. Business Partnering at CALBIO2013 will help attendees to maximize their time and meeting opportunities at the Conference. Once registered for the conference, attendees will be given access to an online dating tool that will allow you to perform quick and advanced searches of companies, products and individual conference attendees to best identify potential business partners. 

Domainex Opens for Business in Boston and San Diego

Domainex Ltd, Europe’s fastest growing drug discovery service company, is pleased to announce its expansion to the US with the appointment of a new business development team and the opening of East and West coast offices in Boston, MA and San Diego, CA. More »
19 July 2018

Owlstone Medical Appoints Five Leading Experts to Scientific Advisory Board

Additions form a key strategic resource to advise on Breath Biopsy platform, product, and study development. More »
19 July 2018

AMSBIO has Introduced New Powerful CRISPR/Cas9 Gene Editing Kits

AMSBIO has introduced new CRISPR / Cas9 editing kits for gene knock-out, gene knock-in and gene mutation applications. More »
18 July 2018

Silence Therapeutics Appoints David Horn Solomon as Chief Executive Officer

Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery and development of novel RNA therapeutics announces today the appointment of Dr David Horn Solomon as its new Chief Executive Officer (CEO) effective immediately. David will head the Leadership Team and joins the Board of Directors. More »
18 July 2018

Wickham Laboratories Announce Latest Article on Sterility Testing Environments and the Vital Role of Isolators

Wickham Laboratories is pleased to announce our latest article published by Cleanroom Technology, “Isolator sterility put to the test,” written by our Sterility Section Head, Stacey Orley. More »
16 July 2018

One Nucleus Recruit New Video Partner

One Nucleus, Europe’s largest membership organisation for companies working within the Life Science and Healthcare industry has added Giggabox to its Partner Programme. Giggabox will play an influential and visible role in the development of the One Nucleus life science community by crafting explainer videos and developing corporate films for members at preferential rates. More »
12 July 2018

PiR’s Diversity Report Findings

“Females are likely to be the highest earner in their household”; this is one of the findings from PiR’s recent Diversity Survey for senior executives in the life science industry. PiR commissioned the Survey to identify if there is any disparity of reward focused around gender within the life science sector. More »
09 July 2018

Abingworth Raises $315m for ABV VII

Abingworth, the international investment group dedicated to life sciences, today announced the final closing of its latest fund, Abingworth Bioventures VII (ABV VII) at $315 million. More »
09 July 2018

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

Acquisition strengthens BioIVT’s transporter sciences capabilities and enables it to partner with customers on new drug applications and mechanistic studies related to transporters. More »
09 July 2018

AMSBIO Launch New Screening Company

ScreenIn3D (Glasgow, UK) is a new joint venture company set up by AMSBIO and the University of Strathclyde exploiting the latest advances in microfluidics and 3D culture to develop a novel microfluidic screening platform. More »
05 July 2018

<< Previous   Page 1 of 43   Next >>